Attached files
| file | filename |
|---|---|
| EX-99.3 - UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, - Kintara Therapeutics, Inc. | ea125914ex99-3_kintara.htm |
| EX-99.2 - UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ADGERO AS OF MARCH 31, - Kintara Therapeutics, Inc. | ea125914ex99-2_kintara.htm |
| EX-99.1 - CONSOLIDATED FINANCIAL STATEMENTS OF ADGERO AS OF DECEMBER 31, 2019 AND 2018, AN - Kintara Therapeutics, Inc. | ea125914ex99-1_kintara.htm |
| 8-K/A - AMENDMENT TO FORM 8-K - Kintara Therapeutics, Inc. | ea125914-8ka_kintara.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT AUDITORS
We have issued our report dated April 9, 2020 with respect to the consolidated financial statements of Adgero Biopharmaceuticals Holdings, Inc. and Subsidiary, which are included in the Current Report on Form 8-K/A of Kintara Therapeutics, Inc. filed August 24, 2020,.
/s/ Rosenberg Rich Baker Berman & Company
Somerset, New Jersey
August 24, 2020